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Abstract
Background: Myocardial fibrosis is being increasingly recognised as a common final pathway of a wide range of
diseases. Thus, the development of an accurate and convenient method to evaluate myocardial fibrosis is of major
importance. Although T1 mapping is a potential alternative for myocardial biopsy, validation studies are limited to
small numbers and vary regarding technical facets, and include only a restricted number of disease. A systematic
review and meta-analysis was conducted to objectively and comprehensively evaluate the performance of T1
mapping on the quantification of myocardial fibrosis using cardiovascular magnetic resonance (CMR).
Methods: PubMed, EMBASE and the Cochrane Library databases were searched for studies applying T1 mapping to
measure myocardial fibrosis and that validated the results via histological analysis. A pooled correlation coefficient
between the CMR and histology measurements was used to evaluate the performance of the T1 mapping.
Results: A total of 15 studies, including 308 patients who had CMR and myocardial biopsy were included and the
pooled correlation coefficient between ECV measured by T1 mapping and biopsy for the selected studies was 0.884
(95% CI: 0.854, 0.914) and was not notably heterogeneous chi-squared = 7.44; P = 0.489 for the Q test and I^2 = 0.00%).
Conclusions: The quantitative measurement of myocardial fibrosis via T1 mapping is associated with a favourable
overall correlation with the myocardial biopsy measurements. Further studies are required to determine the calibration
of the T1 mapping results for the biopsy findings of different cardiomyopathies.
Keywords: Cardiovascular magnetic resonance, T1 mapping, Myocardial fibrosis
Background
Myocardial fibrosis is a common histological characteris-
tic of various heart conditions, from advanced aging to
diseases such as myocardial ischemia, aortic stenosis,
hypertrophic cardiomyopathy (HCM) and dilated cardio-
myopathy (DCM) [1, 2]. A close relationship between
myocardial fibrosis and the development of myocardial
dysfunction, including impaired relaxation, precipitation
of arrhythmias and impaired contractile ability [3] is as-
sociated with a wide range of diseases. Thus, the degree
and distribution of the fibrosis can serve as key indica-
tors for disease development, mortality [4], as well as
prognosis [5, 6]. Therefore, the development of an ac-
curate and convenient way to measure and assess myo-
cardial fibrosis is of clinical significance.
Traditionally, endomyocardial biopsy (EMB) was the
only method by which to visualise and measure the col-
lagen volume fraction (CVF) to determine the degree of
fibrosis. Nevertheless, the clinical application of EMB is
largely limited by its invasiveness, requirements for
skilled operators, the patient factors [7], and sampling
bias. Recently, the establishment of T1 mapping Cardio-
vascular Magnetic Resonance (CMR) [8], provides a
novel and non-invasive method of visualising and quan-
tifying myocardial fibrosis (Fig. 1). This quantification
includes native or pre-contrast T1, post-contrast T1 and
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the expansion of the myocardial extracellular volume
(ECV). Pre-contrast T1 and post-T1 are used before and
after gadolinium injection respectively, and ECV measures
the extracellular volume after gadolinium injection [9]. To
date, three main IR-prepared CMR sequences are used in
T1 mapping including standard Look-Locker(LL) se-
quence, modified Look-Locker MOLLI sequence and
shortened-MOLLI (ShMOLLI) sequence, according to the
previous reviews over techniques [10]. Several studies
have been performed to examine the correlation between
the T1 mapping results and the collagen measured via
biopsies; the majority of the validation studies show favor-
able correlation. However, these studies are limited by
small subject numbers and vary regarding the technical
details, as well as the disease types included. A previous
review on T1 mapping also mentioned the need to exam-
ine and compare the three frequently used means of inter-
preting T1 mapping results to provide a more systematic
and credible evaluation of the performance of T1 mapping
for the assessment of myocardial fibrosis [11]. To date, there
have been no quantitative systematic reviews summarising
the validation tests. Therefore, we conducted a systematic
review and meta-analysis to objectively evaluate the per-
formance of T1 mapping for quantitative measurement of
myocardial fibrosis using CMR. We also summarised the
variations in the technical details used in these studies to
provide possible avenues for further research in this field.
Methods
Search strategy
Computerised bibliographic search of the online data-
bases was performed using PubMed, EMBASE and the
Cochrane Library. We also performed a hand-search for
publications through the references listed in the selected
studies. Moreover, we also searched within specific jour-
nals related to cardiac imaging, including Radiology,
Circulation, JACC, Journal of Cardiovascular Magnetic
Fig. 1 The graph on the left shows recovery curves for a septal region of interest and the blood pool, generated from images at the
corresponding time point (a) (b) (c) in the recovery curves, shown in the bottom row, taken at different times after an inversion pulse at time =
0. The T1 for each pixel location can be used to generate a T1 map, as shown in the top-right images, and performing this technique for all pixels
in the image yields a colored T1 MOLLI map (bottom right)
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Resonance and the European Heart Journal. No limits
were set regarding language and any foreign papers were
translated.
We confined the publication date to between 2005 and
2015. Our searches were performed using variations or com-
binations of the following keywords: ‘magnetic resonance im-
aging’; ‘Cardiovascular Magnetic Resonance (CMR)’; ‘T1
mapping’; ‘myocardial extracellular volume (ECV)’; ‘myocar-
dial fibrosis’; ‘diffuse fibrosis’; ‘validation’; ‘endomyocardial bi-
opsy (EMB)’and ‘collagen volume fraction (CVF)’.
Study selection
The eligibility of studies was independently assessed by
two reviewers in an unblinded and standardised manner.
Any disagreement was resolved by discussion and
referring the study to a third reviewer. Based on the
Preferred Reporting Items for Systematic Reviews and
Meta-analysis (PRISMA) guidelines, the selection of
studies was based on the type of disease, the methods
used to perform T1 mapping, the procedures used for
the biopsy and histochemical analyses of the CVF, and
the appropriateness of the statistical methods used to
test and present the correlation results. Since it remains
an issue of debate as to which sequence is the best for
performing T1 mapping and previous studies did not
show significant differences in their ability to quantify
fibrosis via different scan sequences [12–15], we did not
exclude any studies due to the use of different scan
sequences, provided that the T1 mapping for analysis
was aquired appropriately.
Studies were selected for further analysis if they met
the following criteria: 1) indicated the specific disease
types and number of patients recruited in the study; 2)
applying either appropriate technology (i.e. EQ-CMR,
MOLLI, ShMOLLI, FLASH and Look-Locker) to acquire
T1 mapping images and using one or a combination of
the native T1 time, post-contrast T1 time and ECV to
present the results, and using a magnetic field ≥1.5 T; 3)
validating the quantitative imaging results with CVF
measured from a biopsy and 4) appropriate statistical
methods applied to calculate the validation results and
interpret the results in either r or r2.
Studies were excluded if they: 1) did not perform
quantitative validation tests or provide specific correl-
ation coefficients; 2) did not apply T1 mapping-related
imaging methods to acquire the ECV and 3) were studies
using in vitro or animal models. Finally, if two or more
studies reported the same experiment, we selected the
one that was the most informative.
Quality assessment
The study design, patients recruited and statistical
methods applied in each study were considered primarily
for the quality assessment of the study by referring to the
items in The Quality Assessment of Diagnostic Studies
(QUADAS). QUADAS is a tool developed in 2003 [16, 17]
and renewed in 2011 [18] that is used to assess the quality
of diagnostic studies. Fourteen items were considered with
this tool to rate the index and reference standard tests.
Data extraction
To best extract the data from studies and avoid bias, we
prepared a data extraction sheet based on the data ex-
traction template provided by Cochrane Consumers and
the Communication Review Group. Two authors simul-
taneously extracted the data and checked the extracted
data for each other. Any disagreements were settled by
referring the data to a third author and were decided by
a discussion between the three individuals. We collected
and recorded the following details for data analysis: rec-
ord number, author, article title, the year of publication,
publication (journal), study design, inclusion/exclusion
criteria, imaging methods (e.g. sequence and magnetic
field), the number of patients included, statistical
analysis methods and outcomes (Pearson or Spearman
correlation coefficient (r) and 95% confidence intervals
(CIs) were calculated). For the correlation coefficients,
we recorded the |r| between the histology results and
the three main T1 mapping measurements, including
the ECV, post-contrast T1 time and native T1 time.
To calculate the CIs for each correlation coefficient,
we performed a Fisher’s r-to-z transformation of the
Pearson coefficients to convert each correlation coeffi-
cient into an approximately normal distribution and
then acquired the upper and lower confidence intervals
accordingly [19].
Define:
z ¼ 0:5 ln 1þ rj j
1− rj j
 
zl ¼ z− 1:96ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N−3
p zu ¼ zþ 1:96ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N−3
p






To qualitatively summarise the results of different
studies, we recorded and compared the technical differ-
ences for T1 mapping and any variations of the correl-
ation results while T1 mapping was used in a different
group of patients to further discuss the characteristics.
Data synthesis
Our analysis included the summary estimates of the cor-
relation coefficients to assess the overall correlation be-
tween the CMR measurements with the histology
results. Thus, for the pooled estimates of the correlation
coefficients, we computed the summary statistics across
the individual studies. These were then combined to
produce the pooled estimates of the correlation coeffi-
cients and confidence intervals for the comparison,
which were weighted according to the number of
Diao et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:92 Page 3 of 11
patients in the sample. The meta-analysis was performed
using the fixed effect or random model to combine and
calculate the cumulative effects of the correlation coeffi-
cients according to the heterogeneity of the data; this
was assessed using both the Cochran Q test and the I2
statistic, based on the percentage of the total variation
among the studies instead of chance. P < 0.05 for the Q
test or I2 statistic >50% indicated the presence of signifi-
cant heterogeneity across the selected studies and a
random-effect model was then applied to calculate the
tau value. For the limited number of the studies that
were finally included, the quality of the correlation could
not simply be classified according to previous studies.
We did not perform an analysis of publication bias and
we used Stata/SE 12 to perform the meta-analysis.
Search strategy and study selection
The online search initially yielded 868 literature citations.
In total, 628 studies were excluded after reviewing the ti-
tles and keywords due to a lack of relevance. One author
reviewed 240 abstracts and selected 29 studies for the full-
text evaluation. Further reading excluded additional pa-
pers according to the criteria defined above. Seven studies
were ruled out for not using CVF or contrast-enhanced
T1 mapping as an assessment method. Five studies were
excluded due to the lack of reported correlation coeffi-
cients and two were excluded due to the use of animal
models or post-mortem analyses.
Finally, 15 studies published from 2010 to 2015 fulfilled
our inclusion criteria and 23 experimental results were ana-
lysed because some of the studies included both ECV and
pre- or post-contrast T1 relaxation time as the CMR mea-
surements. The PRISMA flow chart depicting the process of
the systematic literature search and study selection is illus-
trated in Fig. 2. Five studies were from conference articles.
Results
Study design characteristics
The detailed information for the 15 selected studies is
presented in Table 1. The total number of patients re-
cruited in the studies was 308. The patients were diag-
nosed with a wide range of heart diseases, including
Fig. 2 Flow diagram of the study selection process
Diao et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:92 Page 4 of 11
valvular heart disease (113), cardiomyopathy (113) and
heart failure or dysfunction caused by other reasons (e.g.
cardiac amyloidosis) (82). Three studies applied the
ShMOLLI sequence followed by the process described by
Piechnik. Another 3 studies applied FLASH and 7 studies
applied MOLLI for T1 mapping. Moreover, one study ap-
plied equilibrium contrast and one study used Look-
Locker for T1 mapping. All of the selected experiments
provided credible data. In four studies, the correlation co-
efficient was expressed as r2 and another study used
Kendall’s test to calculate the correlation coefficient.
All of the studies excluded patients who had contraindi-
cations to CMR or the contrast agent, as well as patient
data after considering the imaging quality. Among the
studies reporting exclusion details: four studies [20–23]
reported excluding patients with significant coronary ar-
tery disease or myocardium infarction that was too severe
and another three studies [24, 25] reported excluding pa-
tients with severe arrhythmia. Two studies [26, 27] were
reported to exclude patients based on their inability to
hold their breath during CMR. Furthermore, one study
[28] also excluded patients with other organ dysfunction,
such as renal failure.
The quality assessment results are presented in Fig. 3
and the items are shown in Table 2. Although all studies
provided detailed information pertaining to the type of
disease included, the CMR findings, as well as the
technology they used to acquire the T1 mapping, the
majority of studies did not clearly state the time interval
between the CMR and biopsy measurements. There
were 12 out of 15 studies that clearly indicated the ana-
lysis of the CMR and biopsy results were blinded.
Quantitative review
Following the Fisher’s r-to-z transformation method, we
obtained the CIs for 11 out of 15 studies since this trans-
formation is preferred when the number of patients is
greater than ten. The results are presented in Table 3.
For the 11 studies we chose, nine studies reported ECV,
five reported the post-contrast T1 time and three studies
reported the native T1 time as the quantitative T1 map-
ping results.
The pooled r for the nine studies describing the overall
estimated correlations between CVF and ECV was 0.88
(95% CI:0.854, 0.914) and was not notably heteroge-
neous (chi-squared = 7.44, P = 0.489 for the Q test and
I2 = 0.00%) (Fig. 4). On the other hand, the pooled |r| for
the other five studies applying post-contrast T1 by mer-
ging the correlations between CVF and the post-contrast
T1 time was 0.65 (95% CI: 0.53, 0.79) and was also not
notably heterogeneous (chi-squared = 1.68, P = 0.795 for
the Q test and I2 = 0.00%) (Fig. 5). For the native T1
time, only two studies provided available data. The cal-
culated pooled |r| was 0.66 (95% CI: 0.50, 0.87) and was
Table 1 included studies and patients’ characteristics. AS: aortic stenosis; HCM: hypertrophic cardiomyopathy; DCM: dilated
cardiomyopathy; MR: mitral regurgitation; ARVD: arrhythmogenic right ventricular dysplasia; HFpEF: heart failure with preserved
ejection fraction; HFrEF: heart failure with reduced ejection fraction; ICM: ischemic cardiomyopathy
Year Author Journal Number of patients Field Disease type Scan
2010 F.A.S [28] circulation 26 1.5 T AS(18) HCM (8) EQ-CMR
2012 WSK [27] JCMR 12 1.5 T AS (12) shMOLLI
2012 FM [26] JCMR 18 1.5 T AS(18) shMOLLI
2013 WSK [24] JACC 18 1.5 T AS (18) shMOLLI
2013 MCA [22] Circulation 6 1.5 T DCM(3) ischemia (3); MOLLI
2014 ADSP [37] JCMR 24 1.5 T DCM(24) MOLLI
2015 GY [20] JCMR 20 3 T DCM (20) MOLLI
2015 DMDRC [21] JCMR 31 3 T SAS (12),severe aortic
regurgitation (9),MR (10)
MOLLI
2015 KA [35] JCMR 36 1.5 T heart failure (HFpEF (22),
cardiac amyloidosis (7),
HFrEF (3), MR (4))
MOLLI
2015 LG [38] JCMR 4 1.5 T AS (4) MOLLI
2016 KA [39] JACC 36 1.5 T heart failure (28), valvular
heart disease (8)
MOLLI
2013 MJ [23] Circulation 9 1.5 T HFpEF (9) FLASH
2008 IL [25] JACC 9 1.5 T heart transplantation recipients (9) FLASH
2015 IL [40] EHJ 12 1.5 T HCM(8), DCM (2) ICM(1),restrictive(1) FLASH
2012 SCT [41] Radiology 47 1.5 T DCM(13), myocarditis (11), infiltrative /
restrictive cardiomyopathy(22),suspected ARVD (1)
Look-Locker
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not notably heterogeneous (chi-squared = 0.00, P = 0.96
for the Q test and I2 = 0.00%) (Fig. 6).
Qualitative review
Among the 15 studies that were initially selected, two
used 3 T while the others used 1.5 T MR. No major dif-
ferences were noted. In consideration of the scanning tech-
niques, three studies used the ShMOLLI sequence when
performing the T1 mapping measurements and reported
the advantages of choosing this method [24, 26, 27]. Fonta-
na’s [26] experiments compared the multibreath-hold tech-
niques (e.g. fast low angle single shot inversion recovery;
‘multibreath-hold FLASH-IR’) and ShMOLLI. Moreover,
according to their study, compared to the FLASH-IR tech-
nique, the ShMOLLI method was easier to perform suc-
cessfully on patients and had superior reproducibility and a
higher correlation with the histology CVF% [25].
Similar to the method used to achieve equilibrium dis-
tribution in patients, White’s study [24] compared the
differences between the use of a primed contrast infu-
sion (equilibrium contrast-CMR[EQ-CMR]) and the dy-
namic equilibration achieved by delayed post-bolus
measurements. The results of this study exhibited a
favourable correlation between the ECV measured by
the dynamic equilibration with the CVF acquired from
the biopsy sample (r2 = 0.69). Regardless of the fact that
this correlation was not as high as the EQ-CMR method
(r2 = 0.71), the two methods did not exhibit a significant
difference. The author also suggested the use of the EQ-
CMR method if the ECV was found to be over 0.4.
Fig. 3 Study quality evaluated by QUADAS-2 tool. Grouped bar chart displays the cumulative score of the 15 included studies for each fields of
the QUADAS questions. Green bar = “low” risk, yellow bar = “unclear” risk, and red bar = “high” risk. The questions are listed in Table 2
Table 2 QUADAS-2 questions. Results of the analysis for the
quality evaluation are shown in Fig. 3
QUADAS-2 Question
A. patient selection
Was a consecutive or random sample of patient enrolled?
Was a case control design avoided?
Did the study avoid in appropriate exclusion?
B. index test
were the index test interpreted without knowledge of results of the
reference standard?
if a threshold was used, was pre- specified?
C. Reference standard
Is the reference standard likely results interpreted without knowledge of
the result of the index tests?
D. flow and timing
Was there an appropriate interval between index tests and reference
standard?
Did all the patients receive the same reference standard?
Were all patients included in the analysis?
Table 3 Correlations coefficient between three T1 mapping







MCA, 2013 6 0.95 -
GY, 2010 20 0.67 [0.32, 0.86]
DMDRC, 2012 31 0.15 [–0.22,0.48]
KA, 2015 36 0.66 [0.42, 0.81]
Post-T1 time
MJ,2013 9 0.98 -
IL, 2008 9 0.7 -
IL, 2015 12 0.78 [0.37, 0.94]
SCT, 2012 47 0.57 [0.37, 0.74]
WSK, 2013 18 0.51 [0.06, 0.78]
MCA, 2013 6 0.74 -
DMDRC, 2015 31 0.36 [0.01, 0.63]
KA, 2015 36 0.68 [0.45, 0.82]
ECV
F.A.S, 2010 26 0.89 [0.88,0.96]
WSK, 2012 12 0.75 [0.31,0.93]
FM, 2012 18 0.83 [0.59,0.93]
WSK, 2013 18 0.84 [0.61,0.94]
MCA, 2013 6 0.95 -
ADSP, 2014 24 0.85 [0.68,0.93]
GY, 2015 20 0.71 [0.38,0.88]
DMDRC, 2015 31 0.78 [0.59,0.89]
KA, 2015 36 0.91 [0.83,0.95]
LG,2015 4 0.91 -
KA,2016 36 0.49 [0.19,0.71]
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Concerning the T1 time measurements, one study by
Miller [22] employed the MOLLI bolus method and
found that a 15-min post-contrast T1 time was associ-
ated with a better correlation degree between the ECV
and CVF than the 10-min post-contrast T1 time.
Discussion
Our meta-analysis and systematic review demonstrates a
favorable overall correlation between the CMR measure-
ments and the histological measurements from the bi-
opsy. An accurate calculation of the pre- and post- T1
relaxation time, as well as ECV via T1 mapping can re-
flect the degree of myocardial fibrosis in patients with a
wide range of diseases.
This is the first study to quantitatively combine the
previous histological validation tests using T1 mapping
technology for the measurement of myocardial fibrosis.
The studies we included were modestly selected fo-
llowing the PRISMA guidelines. Quality assessment
through QUADAS reveals that the studies from which
we extracted data, performed credible and high-quality
validation experiments. The heterogeneity test revealed
no heterogeneity among the studies we selected.
Myocardial fibrosis is the final pathway in many dis-
ease states and it can be insidious since only enough
amount of fibrosis or accumulation can induce promin-
ent ventricular incompliance and heart dysfunction. Al-
though being considered as the gold standard, EMB
examination is not routinely recommended. Non-
invasive quantification assessments include serum colla-
gen biomarkers (eg. carboxy-terminal pro-peptide of
pro-collagen type I (PICP) and ratio of matrix metallo-
proteinase type 1 to tissue inhibitor of metalloproteinase
type 1 (MMP-1/TIMP)) and imaging techniques [29].
Previous study reported a moderate correlation between
PICP and CVF (r = 0.471) in hypertensive patients [30]
and according to the recent reviews, CMR techniques
including T1 mapping and Late Gadolinium Enhance-
ment (LGE) have superior specificity than the commonly
used serum biomarkers [31]. In fact, LGE CMR has ex-
cellent performance for the diagnosis of some patients
with myocardial fibrosis and has been recognised as a
replacement approach for the diagnosis of patients with
Fig. 4 Forest plot of the correlation coefficients between ECV and histology CVF measurement
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focal myocardial fibrosis using biopsies [32, 33]; how-
ever, this technology remains limited by its requirement
for normal tissues as reference samples and thus, cannot
provide an accurate evaluation of diffuse myocardial fi-
brosis [34].
Based on an imaging mechanism similar to LGE, T1
mapping is used to map out the image-based signal in-
tensities according to myocardium’s longitudinal relax-
ation time. The differences in signal intensity can be
directly interpreted as variations in the amount of fibro-
sis in the scanned heart tissue. Therefore, it is not neces-
sary to use normal tissues as a standard reference to
interpret the results and both focal and diffuse fibrosis
can be quantified. According to our results, all three of
the T1 mapping measurements can have a favourable cor-
relation with the histological results, which can serve as
the basis for studies that further test the prognostic value
of the T1 mapping results. Among these three methods,
ECV has the highest correlation value (r = 0.88) while na-
tive T1 has the lowest (r = 0.66). Theoretically, with the
use of a contrast injection, the tissue heterogeneity should
be easier to detect since the discrepancies in the washout
time between the fibrotic and normal tissues add to the
gap of the T1 time, as gadolinium can potently shorten
the T1. However, post-T1 can only partly reflect the fibro-
sis since gadolinium does not cross cell membranes and
factors such as renal excretion rate would also have a role.
Thus ECV, after taking the blood gadolinium as a refer-
ence, is supposed to better reflect the collagen content, as
well as the fibrosis degree. Furthermore, a limited num-
ber of studies were used for the pooled r calculation,
in which the native T1 results exhibited relatively
high variability between the different studies. Meester
de Ravenstein et al [21] reported that neither the
amount of LGE nor the native pre-contrast myocar-
dial T1 time were associated with significant correl-
ation results for the histology CVF. In contrast, in
Yoshitaka Goto’s [20] study, the native T1 time exhib-
ited a better correlation with the histology (r = 0.673).
We noted that diffuse myocardial fibrosis might be
better than focal fibrosis for quantification using the T1
mapping technique. Flett et al [28] reported that the ob-
served correlation was higher in myocardial fibrosis with
aortic stenosis than in those with increased focal cardio-
myopathy. One potential reason for this high correlation
with aortic disease might be that the vasodilation and
microcirculation conditions caused by various vascular
abnormalities adds to the accumulation of extracellular
Fig. 5 Forest plot of the correlation coefficients between post-contrast T1 time and histology CVF measurement
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collagen. However, since these substances also contrib-
ute to disease progression and the heart load, the T1
mapping results may still be a better interpretation
under these circumstances rather than techniques that
only take fibrosis into consideration. According to the
study by Andreas et al, the correlation was substantially
greater when they included patients with a diagnosis of
cardiac amyloidosis [35]. In addition, a previous study
[9] assumed that the first clinical application of T1 map-
ping might be to examine myocardial fibrosis in rare dis-
eases and once the diagnosis and prognostic value of
this method is agreed upon, it will aid in the interven-
tion of more common cardiovascular diseases. However,
considering that myocardial fibrosis is a shared patho-
logical characteristic, the presence of good stable corre-
lations and low heterogeneity among the studies we
analysed provides support for T1 mapping.
Study limitations
The major limitation of our study is the limited number
of reports that we included in our meta-analysis. More-
over, due to the rapid development and optimisation of
the T1 mapping sequence, we did not identify a suffi-
cient number of studies for each sequence to conduct a
subtype analysis for T1 mapping according to both the
scanning sequence and the type of diseases that cause
myocardial fibrosis. However, the value of this meta-
analysis is that we attempted to indicate (regardless
of the scanning protocol and aetiology of myocardial
fibrosis) whether quantitative T1 mapping can provide
a useful reference to assess the degree of myocardial
fibrosis.
The pooled r for native T1 is another concern of our
study. Although the pooled r showed a good perform-
ance of native T1 for predicting myocardial fibrosis, the
limited number of studies, as well as the poor quality
made this result less credible. More studies with larger
number of patients and multi-centre study are still
needed to better clarify this issue.
We also included used both 1.5 T and 3 T magnetic
fields to perform T1 mapping. However, there appears
to be some dispute on whether 1.5 T or 3 T will have an
effect on the post-contrast T1 mapping measurements
[36]. Therefore, we did not exclude the two studies that
applied 3 T CMR for T1 mapping.
In addition, a good correlation between the two
methods is not enough to completely replace the EMB
method. Thus, additional studies are still required to de-
termine an optimal and accurate transformation func-
tion from the ECV value or T1 relaxation time to CVF.
Using such information, the clinical application of T1
mapping can be further propagated.
Fig. 6 Forest plot of the correlation coefficients between native T1 time and histology CVF measurement
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Conclusion
The CMR measurements of myocardial fibrosis through
T1 mapping correlates well with the CVF measured
through EMB, especially for patients with diffuse myo-
cardial fibrosis. Further studies are required to test and
acquire the detailed transformation function from the
ECV or T1 time to CVF based on different degrees of
myocardial fibrosis or the type of cardiomyopathy.
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